Overview

PULSAR - A Prospective Study to Evaluate the Utility of Low Doses of the Statins Atorvastatin and Rosuvastatin.

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
To compare reduction of LDL-C and safety between 10mg rosuvastatin and 20mg atorvastatin after 6 weeks treatment
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Atorvastatin
Atorvastatin Calcium
Rosuvastatin Calcium